EATON
Intelligent power management company Eaton today announced it is continuing to expand and evolve its European eMobility business design capabilities, technologies and operations to support global electrified vehicle manufacturers. These upgrades will support Eaton’s efforts in delivering electric vehicle solutions to passenger car, commercial vehicle and off-highway OEMs globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230509005268/en/
Eaton leaders, including Pete Denk, president, Vehicle Group, Eaton (left), Krzysztof Kaszkur, manufacturing manager, eMobility, Eaton (center), and Benito Dominguez, director, Operations, eMobility, Eaton (right), tour the new eMobility manufacturing line at the Vehicle Group’s Tczew, Poland, facility. (Photo: Business Wire)
“The electrification of automotive and commercial vehicle markets requires new capabilities to meet the changing industry,” said Mark Schneider, president, eMobility, Eaton. “We are seeing increasing global demand for electrified vehicle solutions that are designed and produced in our European locations.”
Montrottier producing power electronics components for global EV manufacturers
Eaton’s eMobility business has invested in a state-of-the-art production facility for power electronics components in Montrottier, France. High-volume production is scheduled to begin in mid-2023. The power electronics technologies leverage Eaton’s expertise in managing high-voltage power, resulting in advanced vehicle traction inverters and DC/DC converters with a focus on power density and efficiency.
Tczew facility adding eMobility production
Eaton this year also expanded a current site in Tczew, Poland, to include electrified vehicle capabilities to meet the demand of European and global customers. The transformation of the facility was marked with a celebration for the plant employees, company leadership and government representatives.
“The addition of eMobility products to one of our premier facilities reflects Eaton’s ability to provide its customers the solutions they need during the transition from traditional internal combustion engine vehicles to electrified powertrains,” Schneider said.
Bonn facility designed award-winning Breaktor circuit protection technology
Eaton’s site in Bonn, Germany, has been a sophisticated electrical engineering design and testing facility for many years, focusing on industrial controls and protection and power distribution. The Bonn team is leveraging this electrical expertise and capabilities and applying it to electric vehicle systems with the design of the Breaktor® circuit protection technology – leapfrogging EV circuit protection solutions currently on the market.
This new circuit protection solution was named “Best Technology” in the Electrification category at the Hyundai-Kia Motors Corporation’s annual R&D Partners Tech Day. The recognition follows other recent accolades for Eaton’s Breaktor circuit protection technology, including an Automotive News PACEpilot award and the Gasgoo Award 2022 – Top 100 Players of China’s New Automotive Supply Chain in the powertrain electrification segment.
New site in Karlsruhe, Germany, serves as a base for customer interaction and engineering service
Eaton last year established a new office and laboratory facility in Karlsruhe that contains multiple workstations and a laboratory. Due to its proximity to major manufacturers and suppliers, the new office serves as a base for customer interaction and engineering services in the region. It will soon feature a brand-new innovation and testing lab for the testing of power electronics and power distribution products, enabling rapid turnaround in testing of the latest eMobility products. Eaton also is expanding eMobility production in Gummersbach, Germany, and Györ, Hungary, by leveraging Eaton’s Electrical Sector manufacturing facilities.
Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for our stakeholders and all of society.
Founded in 1911, Eaton is marking its 100th anniversary of being listed on the New York Stock Exchange. We reported revenues of $20.8 billion in 2022 and serve customers in more than 170 countries. For more information, visit www.eaton.com. Follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005268/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom